Safety and immunological effects of recombinant canine IL-15 in dogs
| Autor: | Jeong Won Hong, Yeon-Ju Baek, Ji-Youn Jung, Je-Jung Lee, Do-Hyeon Yu, Cheol-Jung Kim, Yu-Jin Lim, Dong-Jun Shin, Sang-Ki Kim, Soo-Hyeon Lee |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Cytotoxicity Immunologic medicine.medical_treatment CD3 Immunology Biochemistry Granzymes 03 medical and health sciences Leukocyte Count 0302 clinical medicine Dogs Antigens CD medicine Immunology and Allergy Cytotoxic T cell Animals Humans RNA Messenger Molecular Biology Cell Proliferation Interleukin-15 biology business.industry Forkhead Transcription Factors Hematology Acquired immune system NKG2D Lymphocyte Subsets Recombinant Proteins Granzyme B Killer Cells Natural 030104 developmental biology Cytokine Perforin Gene Expression Regulation Interleukin 15 030220 oncology & carcinogenesis biology.protein Leukocytes Mononuclear business K562 Cells T-Box Domain Proteins |
| Zdroj: | Cytokine. 148 |
| ISSN: | 1096-0023 |
| Popis: | Interleukin-15 (IL-15) is a pleiotropic cytokine that plays pivotal roles in innate and adaptive immunity. It is also a promising cytokine for treating cancer. Despite growing interest in its use as an immunotherapeutic, its safety and immunological effects in dogs have not been reported. In this study, healthy dogs were given recombinant canine IL-15 (rcIL-15) intravenously at a daily dose of 20 μg/kg for 8 days and monitored for 32 days to determine the safety and immunological effects of rcIL-15. The repeated administration of rcIL-15 was well tolerated, did not cause any serious side effects, and promoted the selective proliferation and activation of canine anti-cancer effector cells, including CD3+CD8+ cytotoxic T lymphocytes, CD3+CD5dimCD21–, and non-B/non-T NK cell populations, without stimulating Treg lymphocytes. The rcIL-15 injections also stimulated the expression of molecules and transcription factors associated with the activation and effector functions of NK cells, including CD16, NKG2D, NKp30, NKp44, NKp46, perforin, granzyme B, Ly49, T-bet, and Eomes. These results suggest that rcIL-15 might be a valuable therapeutic adjuvant to improve immunity against cancer in dogs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect